Biomarin Pharmaceutical Inc (NAS:BMRN)
$ 67.71 0.64 (0.95%) Market Cap: 12.90 Bil Enterprise Value: 12.45 Bil PE Ratio: 40.54 PB Ratio: 2.38 GF Score: 69/100

Biomarin Pharmaceutical Inc U.S. Food and Drug Administration Approves ROCTAVIAN Call Transcript

Jun 29, 2023 / 08:30PM GMT
Release Date Price: $88.93 (-3.57%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the BioMarin Pharmaceutical, U.S. Food and Drug Administration approves BioMarin's Roctavian, the first and only gene therapy for adults with severe hemophilia A webcast. (Operator Instructions) And please be advised that this call is being recorded. (Operator Instructions).

And now at this time, I'll turn things over to Ms. Traci McCarty, Head of Investor Relations at BioMarin. Traci, please go ahead.

Traci McCarty
BioMarin Pharmaceutical Inc. - Group VP of IR

Thank you, Bill, and thank you all for joining us this afternoon. On the call from BioMarin today, we have JJ Bienaime, Chairman and CEO; Hank Fuchs, President, Worldwide Research and Development; Jeff Ajer, EVP, Chief Commercial Officer; Brian Mueller, EVP, Chief Financial Officer; and Greg Guyer, EVP, Chief Technical Officer, Manufacturing and Tech Operations.

To remind you, this nonconfidential presentation contains forward-looking statements about Roctavian and the business prospects of BioMarin Pharmaceutical Inc., including

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot